TrumpRx and Medicare highlight shifting pharma industry priorities, says GlobalData

The US administration’s TrumpRx initiative and a proposed Medicare incentive rule link drug pricing, tariff policy, and domestic manufacturing in a coordinated push to reshore pharmaceutical production, highlighting shifting industry priorities, says GlobalData, a leading intelligence and productivity platform.

Launched in February 2026, TrumpRx enables cash-paying and uninsured patients to access selected branded medicines at discounts of 50–85% below list price through direct manufacturer arrangements. At the same time, imported patented medicines may face tariffs of up to 100% unless companies align US prices with “most favored nation” (MFN) benchmarks or commit to building US manufacturing capacity. Participation in TrumpRx can serve as evidence of pricing alignment, potentially reducing tariff exposure while offering manufacturers a new high-volume commercial channel.

According to GlobalData’s Bio/Pharmaceutical Outsourcing Report, the policy is reinforced by a proposed rule from the Centers for Medicare & Medicaid Services (CMS), under which hospitals that purchase more than 50% US-made essential medicines and active pharmaceutical ingredients (APIs) would receive additional Medicare payments. CMS cited data indicating that domestic APIs are about 12 times more expensive than foreign alternatives and has opened a 60-day public comment period on how best to strengthen the long-term domestic supply without undermining API investment incentives.

Edita Hamzic, Healthcare Analyst at GlobalData, comments: “TrumpRx is not simply a discount platform; it is part of a broader industrial strategy. By tying MFN-style pricing to tariff relief and manufacturing commitments, the administration is making supply chain location a core commercial consideration. Pricing teams and manufacturing strategists can no longer operate in isolation.”

Several major pharmaceutical companies have announced multi-year US investment plans in biologics and sterile injectable manufacturing amid this evolving policy environment.

The report also notes that the US Food and Drug Administration (FDA) has launched its FDA PreCheck pilot program to streamline domestic facility development, further aligning regulatory policy with trade and pricing measures.

Cyrus Fan, Senior Healthcare Analyst at GlobalData, adds: “The CMS proposal adds a demand-side incentive to the administration’s supply-side strategy. Additional Medicare payments for US-made essential medicines could help offset cost differentials, but hospitals and manufacturers will need clarity on long-term reimbursement stability and API sourcing expectations.”

Additionally, GlobalData highlights that supply chain realignment is accelerating across advanced therapy manufacturing. Akron Biotechnology LLC and Qkine Ltd have formed a strategic partnership to jointly develop and globally supply ancillary materials for stem cell-based therapeutics, combining recombinant protein technologies with GMP manufacturing capabilities. Meanwhile, Fresenius Kabi AG and Cellular Origins Ltd have completed the first phase of a collaboration to scale cell and gene therapy manufacturing using robotics and advanced cell processing technologies.

The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical contract manufacturing organizations. The report lists the latest contract manufacturing agreements, opportunities and threats for CDMOs, M&A and financing of CDMOs, and emerging regulatory news